Literature DB >> 21633320

Absence seizures associated with efavirenz initiation.

Renate Strehlau1, Leigh Martens, Ashraf Coovadia, Collet Dandara, Jennifer Norman, Julia Maisel, Louise Kuhn, Elaine J Abrams.   

Abstract

Efavirenz, used in treating pediatric human immunodeficiency virus infection, has central nervous system side effects. We report on a 5-year-old girl with perinatally acquired human immunodeficiency virus infection, presenting with new onset absence seizures after starting treatment with efavirenz. Plasma efavirenz values were above therapeutic range. The child was homozygous for the CYP2B6-516T/T genotype, which is associated with poor efavirenz clearance. Seizures abated after efavirenz discontinuation.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21633320      PMCID： PMC3278073          DOI： 10.1097/INF.0b013e318223b680

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  21 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.

Authors:  Michelle Viljoen; Hermien Gous; Herculina S Kruger; Alison Riddick; Tammy M Meyers; Malie Rheeders
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

3.  Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Authors:  Akihiko Saitoh; Courtney V Fletcher; Richard Brundage; Carmelita Alvero; Terrence Fenton; Karen Hsia; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

4.  High prevalence of subtherapeutic plasma concentrations of efavirenz in children.

Authors:  Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

5.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

Authors:  Grace McComsey; Nasreen Bhumbra; Jen-Fu Ma; Mobeen Rathore; Ana Alvarez
Journal:  Pediatrics       Date:  2003-03       Impact factor: 7.124

7.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.

Authors:  Julia di Iulio; Aurélie Fayet; Mona Arab-Alameddine; Margalida Rotger; Rubin Lubomirov; Matthias Cavassini; Hansjakob Furrer; Huldrych F Günthard; Sara Colombo; Chantal Csajka; Chin B Eap; Laurent A Decosterd; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2009-04       Impact factor: 2.089

8.  Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.

Authors:  U Wintergerst; F Hoffmann; A Jansson; G Notheis; K Huss; M Kurowski; D Burger
Journal:  J Antimicrob Chemother       Date:  2008-03-13       Impact factor: 5.790

9.  Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.

Authors:  Elizabeth A Lowenhaupt; Kelly Matson; Bushra Qureishi; Akihiko Saitoh; David Pugatch
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

10.  Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

Authors:  Thanyawee Puthanakit; Pranoot Tanpaiboon; Linda Aurpibul; Tim R Cressey; Virat Sirisanthana
Journal:  Antivir Ther       Date:  2009
View more
  7 in total

1.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 2.  The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.

Authors:  Mei Tan; Megan Bowers; Phil Thuma; Elena L Grigorenko
Journal:  New Dir Child Adolesc Dev       Date:  2020-07-12

3.  Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.

Authors:  Ashraf Coovadia; Elaine J Abrams; Renate Strehlau; Stephanie Shiau; Francoise Pinillos; Leigh Martens; Faeezah Patel; Gillian Hunt; Wei-Yann Tsai; Louise Kuhn
Journal:  JAMA       Date:  2015-11-03       Impact factor: 56.272

4.  Reply to Van de Wijer et al.

Authors:  Pamela M Murnane; Renate Strehlau; Stephanie Shiau; Faeezah Patel; Ndileke Mbete; Gillian Hunt; Elaine J Abrams; Ashraf Coovadia; Louise Kuhn
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

Authors:  Janneke H van Dijk; Catherine G Sutcliffe; Francis Hamangaba; Christopher Bositis; Douglas C Watson; William J Moss
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

6.  A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.

Authors:  Nathan Yakubu Shehu; Victor Ojeh; Godwin Osaigbovo; Patricia Agaba; Oche Agbaji
Journal:  J Med Case Rep       Date:  2016-04-13

7.  Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.

Authors:  Francoise Pinillos; Collet Dandara; Marelize Swart; Renate Strehlau; Louise Kuhn; Faeezah Patel; Ashraf Coovadia; Elaine Abrams
Journal:  BMC Infect Dis       Date:  2016-02-02       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.